[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?

Intellia Therapeutics (NTLA) shares charged up on April 27 after the company announced landmark Phase 3 results for its hereditary angioedema (HAE) candidate. This milestone represents the first-ever global Phase 3 data for an in vivo CRISPR therapy, proving the technology is clinically viable. 

Intellia Therapeutics stock has been a lucrative investment in 2026, currently up more than 50% versus the start of this year. 

Fundamentals

See More
  • Market Capitalization, $K 1,540,467
  • Shares Outstanding, K 118,134
  • Annual Sales, $ 67,670 K
  • Annual Income, $ -412,690 K
  • EBIT $ -441 M
  • EBITDA $ -425 M
  • 60-Month Beta 1.99
  • Price/Sales 23.79
  • Price/Cash Flow N/A
  • Price/Book 2.35

Options Overview Details

View History
  • Implied Volatility 77.58% (-22.27%)
  • Historical Volatility 75.35%
  • IV Percentile 15%
  • IV Rank 7.94%
  • IV High 154.61% on 10/27/25
  • IV Low 70.94% on 08/20/25
  • Expected Move (DTE 17) 2.00 (15.13%)
  • Put/Call Vol Ratio 0.64
  • Today's Volume 12,985
  • Volume Avg (30-Day) 3,633
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 89,316
  • Open Int (30-Day) 93,772
  • Expected Range 11.20 to 15.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.92
  • Number of Estimates 8
  • High Estimate $-0.72
  • Low Estimate $-1.10
  • Prior Year $-1.10
  • Growth Rate Est. (year over year) +16.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.62 +13.60%
on 03/30/26
16.97 -22.21%
on 04/23/26
+0.83 (+6.71%)
since 03/27/26
3-Month
10.94 +20.71%
on 02/05/26
16.97 -22.21%
on 04/23/26
-0.62 (-4.49%)
since 01/28/26
52-Week
6.83 +93.27%
on 05/30/25
28.25 -53.27%
on 10/20/25
+4.72 (+55.66%)
since 04/28/25

Most Recent Stories

More News
Intellia Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 13.20 (+1.23%)
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there any further upside left in NTLA shares?

REGN : 731.77 (-1.70%)
NTLA : 13.20 (+1.23%)
3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 30.56 (+4.78%)
CRSP : 52.06 (+2.10%)
MRK : 110.03 (-0.18%)
BMY : 58.26 (+0.83%)
NTLA : 13.20 (+1.23%)
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 13.20 (+1.23%)
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints;  favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from...

NTLA : 13.20 (+1.23%)
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

World’s first Phase 3 readout for an  in vivo CRISPR gene editing candidate Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE...

NTLA : 13.20 (+1.23%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 13.20 (+1.23%)
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector

With $116 million in FY2025 product revenue and a $2.0 billion cash reserves, CRSP has separated itself from pre-commercial peers — but the path forward demands clear eyes on both opportunity and risk....

CRSP : 52.06 (+2.10%)
EDIT : 3.06 (+5.88%)
NTLA : 13.20 (+1.23%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 13.20 (+1.23%)
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.3480 (+5.45%)
NAGE : 4.84 (-2.42%)
GERN : 1.5100 (-1.31%)
NTLA : 13.20 (+1.23%)
OCGN : 1.6600 (-2.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 15.44
2nd Resistance Point 14.80
1st Resistance Point 14.00
Last Price 13.20
1st Support Level 12.56
2nd Support Level 11.92
3rd Support Level 11.12

See More

52-Week High 28.25
Fibonacci 61.8% 20.07
Fibonacci 50% 17.54
Fibonacci 38.2% 15.01
Last Price 13.20
52-Week Low 6.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.